Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending‐dose study in healthy young men

Documenti analoghi

• Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
  di: Yun Liu, et al.
  Pubblicazione: (2024)
• Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine
  di: Craig M. Comisar, et al.
  Pubblicazione: (2024)
• Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants
  di: Jean‐Yves Gillon, et al.
  Pubblicazione: (2025)
• Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers
  di: William K. Schmidt, et al.
  Pubblicazione: (2024)
• Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
  di: Richard Bertz, et al.
  Pubblicazione: (2025)